Clinical trials: Renal Denervation
Hypertension
EnligHTN IV Trial - Multicenter Sham-controlled RCT of Renal Denervation for Hypertension
The purpose of the EnligHTN IV clinical investigation is to demonstrate the safety and effectiveness of the EnligHTN™ Renal Denervation System in the treatment of subjects with drug-resistant uncontrolled hypertension.
- Trial name
- EnligHTN-IV (NCT01903187)
- Testing
- EnligHTN Renal Denervation
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Abbott Medical Devices
Hypertension
Renal Denervation for the Treatment of Hypertension: A Pilot Safety and Efficacy Study
A single center, self-controlled pilot study on safety and efficacy of renal denervation in treatment of hypertension.
- Trial name
- NCT02672462
- Testing
- Radio frequency renal denervation system (Golden Leaf GL-06E15A)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Golden Leaf MedTec Co. Ltd
Hypertension, Cardiovascular Diseases
Longitudinal Real-world Clinical Outcomes Study on Symplicity Renal Denervation
This observational study will assess the long-term effectiveness of the RDN procedure for lowering blood pressure in Medicare patients with uncontrolled hypertension.
- Conditions
- Hypertension, Cardiovascular Diseases, Vascular Diseases
- Trial name
- SPYRAL CARE (NCT07174622)
- Testing
- Renal Denervation (Symplicity Spyral™)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Medtronic Vascular
Metabolic Syndrome
Renal Sympathetic Denervation in Metabolic Syndrome (Metabolic Syndrome Study)
The purpose of this clinical investigation is to determine the effects of renal sympathetic denervation on insulin resistance and muscle sympathetic nerve activity in patients with metabolic syndrome.
- Trial name
- NCT01911078
- Testing
- Renal Denervation, EnligHTN™ Renal Denervation System.
- Where
- Greece
- Volunteers
- 20 people
- Sponsor
- Abbott Medical Devices
Primary Hypertension
Renal Denervation by Iberis MultiElectrode Renal Denervation System in Patients With Primary Hypertension
The purpose of Iberis-HTN trial is to evaluate the safety and effectiveness of renal denervation in subjects with primary hypertension by using Iberis multielectrode renal denervation system
- Trial name
- Iberis-HTN (NCT02901704)
- Testing
- Renal Denervation System (AngioCare)
- Volunteers
- 216 people
- Sponsor
- Shanghai AngioCare Medical
Hypertension, Resistant to Conventional Therapy
Continued Safety and Performance of the TIVUS System
The TIVUS II is a prospective, multicenter, non-randomized, open-label clinical study of the safety and performance of the TIVUS™ System consisting of three (3) concurrent cohorts: TIVUS™ Severe Resistant HTN Cohort TIVUS™…
- Trial name
- NCT01835535
- Testing
- TIVUS
- Where
- Australia
- Volunteers
- 80 people
- Sponsor
- Cardiosonic
Essential Hypertension
Safety and Efficacy of Modulated Ultrasound Renal Denervation for HTN（FIM）
This study is a prospective and exploratory clinical study, enrolling patients with essential hypertension. This study is planned to be conducted in 2 research institutions in China, and a total of 6 subjects are planned to be…
- Trial name
- ModulationHTN1 (NCT06877234)
- Testing
- Ultrasonic Nerve Ablation System
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Shenzhen Pulsecare Medical Technology Co., Ltd.
Uncontrolled Hypertension
Renal Denervation in Patients With Uncontrolled Hypertension (Symplicity HTN-2)
An international, multi-center, prospective, randomized, controlled study of the safety and effectiveness of renal denervation in patients with uncontrolled hypertension.
- Trial name
- HTN-2 (NCT00888433)
- Testing
- Renal Denervation (Symplicity® Renal Denervation System)
- Where
- 20 sites in Australia, Austria and 8 more
- Volunteers
- 106 people
- Sponsor
- Medtronic Vascular
Kidney Failure, Chronic, Renal Dialysis
Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension
The purpose of this this study is to investigate the clinical utility of renal denervation in the treatment of ESRD patients with refractory hypertension.
- Trial name
- NCT00753116
- Testing
- Renal Denervation with a catheter-based procedure
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medtronic Vascular
Hypertension, Renal Denervation
International First-in-Human Study of the EnligHTN Generation 2 System in Patients With Drug-resistant Uncontrolled Hypertension
The purpose of this First-in-Human Clinical investigation is to evaluate the safety and performance of the St. Jude Medical EnligHTN™ Generation 2 Renal Denervation System for the treatment of patients with drug-resistant…
- Trial name
- EnligHTN III (NCT01836146)
- Testing
- EnligHTN™ Renal Artery Ablation Catheter
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 39 people
- Sponsor
- Abbott Medical Devices
Resistant Hypertension
Renal Sympathetic Denervation by Iberis System in Patients With Uncontrolled Hypertension - Iberis-HTN Registry
The purpose of this study is to document safety and efficacy of renal sympathetic denervation treatment in subjects with uncontrolled hypertension by using Iberis renal denervation system.
- Trial name
- Iberis (NCT02295683)
- Testing
- Renal Denervation
- Where
- 2 sites in Serbia, Spain
- Volunteers
- 18 people
- Sponsor
- Terumo Europe N.V.
Uncontrolled Hypertension
Renal Denervation by MDT-2211 System in Patients With Uncontrolled Hypertension
The objective of this study is to demonstrate that the MDT-2211 renal denervation system is a safe and effective treatment for uncontrolled hypertension subjects despite treatment with 3 or more anti-hypertensive medications of…
- Trial name
- HTN-J (NCT01644604)
- Testing
- MDT-2211 Renal Denervation System
- Where
- 17 sites in Japan
- Volunteers
- 41 people
- Sponsor
- Medtronic Vascular
Hypertension
The Peregrine Post-Market Study for the Treatment of Hypertension
The Ablative Solutions, Inc. Peregrine System Infusion Catheter is a catheter-based device which is intended to be used to ablate the afferent and efferent sympathetic nerves serving the kidneys.
- Trial name
- NCT02570113
- Testing
- Peregrine System Infusion Catheter
- Where
- 10 sites in Belgium, Czechia and 2 more
- Volunteers
- 45 people
- Sponsor
- Ablative Solutions, Inc.
Hypertension
Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)
The REDUCE HTN: REINFORCE study is being conducted to determine whether the Vessix Reduce™ Catheter and Vessix™ Generator for the treatment of uncontrolled hypertension (off-treatment office systolic blood pressure ≥150 mmHg and…
- Trial name
- NCT02392351
- Testing
- Renal Denervation (Vessix), Renal Angiography
- Where
- 12 sites in United States
- Volunteers
- 51 people
- Sponsor
- Boston Scientific Corporation
Uncontrolled Hypertension
SYMPLICITY HTN-3 Renal Denervation in Patients With Uncontrolled Hypertension
The Symplicity HTN-3 study is a, multi-center, prospective, single-blind, randomized, controlled study of the safety and effectiveness of renal denervation in subjects with uncontrolled hypertension.
- Trial name
- NCT01418261
- Testing
- Renal denervation (Symplicity Catheter System), Renal angiogram
- Where
- 79 sites in United States
- Volunteers
- 535 people
- Sponsor
- Medtronic Vascular
Multivessel Coronary Artery Disease, Hypertension Resistant to Conventional Therapy
Expand Management of Blood Pressure With Renal Denervation in Patients Undergoing Staged PCI for Advanced Coronary Artery diseasE
EMBRACE is a randomized, controlled, multicenter clinical study evaluating the effect of renal denervation on clinical adverse events in hypertensive patients undergoing staged percutaneous coronary intervention (PCI) for…
- Trial name
- EMBRACE (NCT07602790)
- Testing
- Renal denervation
- Volunteers
- 1,000 people
- Sponsor
- Ceric Sàrl
Resistant Hypertension
TrAnsCatHeter Intravascular Ultrasound Energy deliVery for rEnal Denervation (ACHIEVE)
The ACHIEVE study is a single-arm, open-label, prospective, post-market follow-up study to include up to one hundred (100) eligible patients as defined within the clinical investigational plan, with a twelve month follow-up…
- Trial name
- ACHIEVE (NCT01789918)
- Testing
- PARADISE percutaneous renal denervation
- Where
- 8 sites in Germany, Netherlands and 1 more
- Volunteers
- 96 people
- Sponsor
- ReCor Medical, Inc.
Resistant Hypertension, Uncontrolled Hypertension
Rapid Renal Sympathetic Denervation for Resistant Hypertension II
This is a global, multi-center, prospective, randomized, controlled study of the safety and effectiveness of renal denervation with the OneShot Renal Denervation System in patients with uncontrolled hypertension.
- Conditions
- Resistant Hypertension, Uncontrolled Hypertension, Renal Artery Ablation
- Trial name
- RAPID II (NCT01939392)
- Testing
- Renal Denervation (OneShot™ Renal Denervation System)
- Where
- Italy
- Sponsor
- Medtronic Endovascular
Resistant Hypertension
Symplicity China Study
The Symplicity China study will evaluate the real-world long-term safety, efficacy, and durability of the Symplicity Spyral system in a population of approximately 500 renal denervation treated subjects with up to 36 months of…
- Trial name
- NCT07081243
- Testing
- Symplicity Spyral Renal Denervation System
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Medtronic Vascular
Uncontrolled Essential Hypertension
Ultrasound Ablation for Essential Hypertension（FIM）
To evaluate the safety and feasibility of disposable intravascular ultrasound ablation catheter and ultrasound ablation instrument in the treatment of essential hypertension.
- Trial name
- NCT05795829
- Testing
- disposable intravascular ultrasound ablation catheter and ultrasound ablation instrument
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Lepu Medical Technology (Beijing) Co., Ltd.